Comparison · Care Model
Medical Weight Loss vs. GLP-1 Alone: A Physician's Comparison (2026)
| Attribute | Medical Weight Loss Program Physician-supervised | GLP-1 Alone Telehealth script / med-spa |
|---|---|---|
| Care model | Board-certified physician owns diagnosis, titration, monitoring, maintenance | Online questionnaire, recurring prescription delivery, minimal follow-up |
| Baseline workup | Full labs, hormone panel where indicated, body composition (DEXA / BIA) | None to minimal |
| Medication product | FDA-approved brand (Wegovy, Zepbound, etc.) | Often compounded semaglutide / tirzepatide (not FDA-approved) |
| Titration | Individualized to tolerability and response | Fixed schedule with no clinician judgment |
| Lean-mass protection | Protein-targeted nutrition + structured resistance training | Not addressed |
| Side-effect management | Same-day clinician access; dose pause and reassessment available | Asynchronous messaging; limited dose flexibility |
| Body-composition monitoring | Quarterly DEXA or BIA | None |
| Maintenance plan | Defined before the loss phase ends | Subscription continues or ends; no structured taper |
| Typical monthly cost (June 2026) | $600 – $1,800 total (medication + care + labs) | $200 – $400 (compounded) or $349 – $499 (manufacturer self-pay) |
What the Models Actually Are
Two products that look similar and are not
A standalone GLP-1 subscription is a transaction: a short online questionnaire, a recurring shipment of medication (frequently compounded), and minimal clinical follow-up. A medical weight loss program is a relationship: a board-certified physician who owns the diagnosis, the medication selection, the titration, the nutrition and resistance-training programming, the body-composition monitoring, and the maintenance plan.
Both models can deliver weight loss in the short term. They differ on what happens to lean mass, what happens when side effects appear, what happens after the loss phase ends, and what happens if the patient has a comorbidity that should change the prescription.
Why the Difference Matters
Lean Mass, Durability, and Safety
Lean mass: any rapid weight loss costs lean tissue. Without protein-targeted nutrition (1.2–1.6 g/kg goal weight) and structured resistance training, 25–40% of weight lost on GLP-1 therapy can be lean mass — which damages metabolic rate, function, and durability. A physician-supervised program builds this protection in from week one.
Durability: trials consistently show meaningful weight regain after stopping GLP-1 therapy (STEP 4: ~6.9% regain on placebo over 48 weeks while continued therapy added ~7.9% loss). A program plans the maintenance phase before the loss phase ends; a subscription typically does not.
Safety: GLP-1 side effects (severe GI symptoms, gallbladder disease, pancreatitis, dehydration with kidney injury, hypoglycemia on concurrent insulin) need rapid clinician access and judgment. Same-day messaging plus structured follow-ups vs. asynchronous tickets are not the same standard of care.
Product integrity: compounded semaglutide and tirzepatide are not FDA-approved. The FDA has documented dosing errors, adverse events, and salt-form substitutions. With both molecules off the FDA shortage list, routine compounding is generally not permitted.
Decision Framework
Which One Is Right for You?
- ·If you have a chronic medical condition (obesity, type 2 diabetes, metabolic syndrome) — choose medical weight loss. That is what these conditions require.
- ·If you want the largest possible loss with preserved lean mass — choose medical weight loss. Body composition is what determines whether you look and feel better, and a program is built around protecting it.
- ·If you want the cheapest possible monthly bill and you accept the risk profile of unregulated compounded medication — a GLP-1 subscription is cheaper. The trade-off is documented; physicians advise against it.
- ·If you have insurance — your office visits, labs, and many medications can be covered. A program structured around insurance billing is often less expensive net of coverage than a flat-fee subscription.
- ·If you do not want a long-term relationship with a physician — neither model is a good fit. Obesity is a chronic condition; an unmonitored medication is not the answer.
“[PHYSICIAN QUOTE — REPLACE] A short, attributable clinical insight from a Haute MD weight-loss physician on the difference patients see between a subscription and a program.”
Frequently asked
Common questions
Is a GLP-1 subscription cheaper than a medical weight loss program?
Often yes on the monthly bill — typically $200–$400 for compounded semaglutide or tirzepatide vs. $600–$1,800 total for a program (medication + visits + labs + body composition). The trade-off is product integrity (compounded GLP-1s are not FDA-approved and physicians advise against them) and the absence of monitoring, nutrition support, lean-mass protection, and maintenance planning.
Will I lose more weight in a medical weight loss program?
The medication does most of the weight-loss work in both models. The difference shows up in body composition, durability, and safety. A program protects lean mass during loss, manages side effects in real time, and plans for maintenance — which is where most subscription users regain.
Do I need a medical weight loss program if my insurance covers Wegovy or Zepbound?
Even with covered medication, the care around it matters. Many primary care physicians comfortable with GLP-1 management run competent informal programs. For patients with metabolic complexity, hormonal drivers, prior failures, or a desire for closer monitoring and body-composition support, a dedicated medical weight loss physician adds clinical value the standard PCP visit cannot.
Is compounded semaglutide or tirzepatide safe?
Compounded GLP-1s are not FDA-approved. The FDA has documented dosing errors, adverse events, and salt-form substitutions (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as the brand-name medications. With both molecules off the FDA shortage list, routine compounding is generally not permitted. Physicians advise against them.
Can I start with a subscription and switch to a real program later?
Yes, and many patients do — usually when side effects become unmanageable, when weight loss plateaus, when they want body-composition monitoring, or when they realize the subscription has no plan for what happens after the loss phase. The earlier the switch, the more lean mass is preserved.
References
Sources
- 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine, 2021.
- 7.Effect of Continued Weekly Semaglutide vs Placebo on Weight-Loss Maintenance (STEP 4) — JAMA, 2021.
- 3.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 2022.
- 4.Tirzepatide vs Semaglutide for Treatment of Obesity (SURMOUNT-5, head-to-head) — New England Journal of Medicine, 2025.
- 8.FDA Warnings on Compounded Semaglutide and Tirzepatide — U.S. Food and Drug Administration, 2024.
Related